BioCardia, Inc. 8-K

What Happened

• On May 8, 2026, BioCardia, Inc. (BCDA) filed an 8-K and issued a press release reporting the outcome of a Pre‑Submission Meeting with the U.S. Food and Drug Administration (FDA) regarding the Helix Transendocardial Delivery Catheter System (Helix). The company reported that the FDA agreed there are two possible pathways for Helix marketing clearance and raised no concerns about Helix safety data, device performance, or compatibility with general classes of agents. The FDA expressed a preference for approving Helix simultaneously with the CardiAMP cell therapy system for heart failure, and also suggested a follow‑on pre‑submission could enable a De Novo pathway.

Key Details

• Date of filing/press release: May 8, 2026.
• FDA raised no concerns regarding Helix safety, device performance, or compatibility with general classes of agents.
• FDA identified two possible approval paths: (1) simultaneous approval with CardiAMP cell therapy (FDA-preferred) and (2) potential De Novo route following a follow‑on pre‑submission.
• The press release is attached to the Form 8‑K as Exhibit 99.1.

Why It Matters

• The FDA’s feedback reduces near‑term regulatory uncertainty by confirming safety and performance data raised no agency concerns.
• FDA preference to tie Helix clearance to CardiAMP approval links Helix’s timing to the regulatory progress of the CardiAMP therapy; the suggested De Novo follow‑on offers an alternate regulatory route.
• For investors, these points are material to BioCardia’s regulatory strategy and potential commercialization timeline for the Helix delivery system.